Catherine Owen Adams, Acadia Pharmaceuticals CEO
Acadia snaps up an essential tremor drug after field's summer setbacks
A few weeks after gaining about $100 million from a priority review voucher, Acadia Pharmaceuticals is putting its money to work by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
